VolitionRx Reports 112% Revenue Growth to $1.38 Million, Faces Increased Losses

VolitionRx Limited has reported its financial results for the six months ending June 30, 2026, revealing a total revenue of $1.38 million, a significant increase of 112% compared to $0.65 million during the same period in 2025. The revenue growth was primarily driven by a substantial rise in product sales, particularly from the Nu.Q® Vet Cancer Test and Nu.Q® Discover kits. However, service revenue saw a decline of 79%, dropping to $58,949 from $277,254, reflecting a shift in client project delivery schedules. The company reported a net loss of $14.02 million for the first half of 2026, compared to a net loss of $11.79 million in the prior year, indicating a 19% increase in losses.

Operating expenses decreased to $10.91 million from $12.47 million year-over-year, largely due to reductions in research and development, general and administrative, and sales and marketing expenses. Research and development costs fell by 13% to $4.65 million, while general and administrative expenses decreased by 6% to $4.86 million. The company attributed these reductions to lower personnel costs and the release of bonus provisions, alongside a decrease in stock-based compensation. The total operating loss for the period was $9.53 million, an improvement of 19% from the previous year's loss of $11.82 million.

In terms of strategic developments, VolitionRx has made significant strides in its commercialization efforts. The company has expanded its product offerings and entered into various licensing agreements with established diagnostic companies, including Werfen and Hologic, to enhance market access for its tests. The Nu.Q® Vet Cancer Test is now available in over twenty countries, and the company has initiated the rollout of its Nu.Q® Lung Cancer test, with plans for clinical certification and reimbursement submissions underway.

Operationally, VolitionRx has seen a reduction in its employee headcount, which has contributed to lower operating expenses. As of June 30, 2026, the company had 36 full-time equivalent personnel in research and development, down from 48 the previous year. The company also reported a cash position of approximately $2.79 million, an increase from $1.12 million at the end of 2025, primarily due to financing activities that raised $12.6 million during the first half of 2026.

Looking ahead, VolitionRx faces challenges related to its ongoing losses and the need for additional capital to sustain operations. The company has indicated that it will continue to seek financing through equity or debt offerings, licensing agreements, and grant funding. Management has expressed a commitment to maintaining tight cost controls while pursuing its strategic goals, although there remains substantial doubt about the company's ability to continue as a going concern without further financing.